Article
Deciphering the Significance of Plasma Chemokines as Prognostic Biomarkers in Pegylated IFN-Α-2a /Ribavirin-Treated Chronic Hepatitis C Genotype 4 Patients.
Infectious disorders drug targets - 1 Jan 2022
Hamed M Haroon, Pushparaj Peter Natesan, Rehman Shafiqur, Al-Karim Saleh, Bazarah Salem, Qadri Ishtiaq
Abstract excerpt
BACKGROUND: Hepatitis C viral (HCV) infection is a major clinical burden globally. Pegylated IFN-α-2a (PEG-IFN-α-2a) with ribavirin (RIB) therapy induces an array of cellular antiviral responses, including dsRNA kinases (PKR), chemokines, and cytokines to tackle the HCV infection. However, many HCV patients develop resistance to PEG-IFN/RIB therapy rendering the therapy ineffective. OBJECTIVES: Here, we assess...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.